Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.
Amgen (AMGN) Q4 2024 Earnings Call Transcript
All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speakers' prepared remarks. In order to ensure that everyone has a chance to participate,
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.
AMGN Earnings: Amgen Slips on Soft EPS Guidance
Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter of Fiscal Year
Amgen Inc. (NASDAQ:AMGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations were $5.04. Operator: My name is Julienne, and I will be your conference facilitator today for Amgen’s Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Q4 2024 Amgen Inc Earnings Call
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
Amgen (AMGN) reported $9.09 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.9%. EPS of $5.31 for the same period compares to $4.71 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $8.
pharmaphorum8mon
Amgen preps Uplizna filing for a second indication
Amgen has moved closer to a second indication for its B cell-depleting therapy Uplizna, acquired as part of its $27.8 billion takeover of Horizon Therapeutics last year, after positive results in ...
Seeking Alpha1mon
Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)
and the neuromyelitis optica spectrum disorder therapy known as Uplizna. Combined, these drugs contributed to a $904 million boost in Amgen's total revenue. The acquisition drove 29% volume growth ...
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.
pharmaphorum1y
Amgen gets Horizon acquisition over the line
Along with Tepezza and Krystexxa, the merger also gives Amgen rights to Uplizna (inebilizumab), a drug for neuromyelitis optica spectrum disorder (NMOSD) that Horizon acquired when it bought Viela ...
Investing13d
Amgen's SWOT analysis: stock poised for growth amid obesity drug potential
Beyond MariTide, Amgen's pipeline includes several other promising candidates: Uplizna: Recently showed favorable Phase III results for generalized myasthenia gravis (gMG) Rocatinlimab ...
Nasdaq27d
Amgen’s Q4 2024 Earnings: What to Expect
Thousand Oaks, California-based Amgen Inc. (AMGN) discovers, develops, and manufactures innovative medicines aimed at improving the lives of millions. With a market cap of $142 billion ...
Hosted on MSN23h
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...
Amgen targets $34.3B-$35.7B in 2025 revenues with strong growth in key therapeutic areas
Q4 2024 Management View Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in ...